CareDx, Inc (NASDAQ:CDNA) Shares Bought by US Bancorp DE

US Bancorp DE raised its holdings in CareDx, Inc (NASDAQ:CDNA) by 907.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,168 shares of the company’s stock after buying an additional 15,464 shares during the period. US Bancorp DE’s holdings in CareDx were worth $368,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Quarry LP acquired a new stake in CareDx in the third quarter valued at $27,000. Harvest Fund Management Co. Ltd purchased a new position in shares of CareDx during the third quarter worth about $52,000. KBC Group NV purchased a new position in shares of CareDx during the third quarter worth about $99,000. Quest Partners LLC grew its holdings in shares of CareDx by 37.8% during the third quarter. Quest Partners LLC now owns 5,611 shares of the company’s stock worth $175,000 after purchasing an additional 1,540 shares during the last quarter. Finally, Captrust Financial Advisors purchased a new position in shares of CareDx during the third quarter worth about $271,000.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on CDNA shares. Stephens reaffirmed an “overweight” rating and set a $40.00 price objective on shares of CareDx in a report on Thursday, February 27th. StockNews.com raised CareDx from a “hold” rating to a “buy” rating in a report on Wednesday, February 26th. HC Wainwright dropped their price objective on CareDx from $26.00 to $25.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. Finally, Wells Fargo & Company raised CareDx from an “underweight” rating to an “equal weight” rating and lowered their price target for the stock from $28.00 to $24.00 in a report on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.83.

CareDx Stock Down 6.8 %

NASDAQ CDNA opened at $17.64 on Friday. CareDx, Inc has a 52-week low of $7.42 and a 52-week high of $34.84. The business’s 50-day moving average price is $22.31 and its 200 day moving average price is $24.49. The firm has a market cap of $977.71 million, a P/E ratio of -6.53 and a beta of 1.95.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $1.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $1.46. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The company had revenue of $86.58 million for the quarter, compared to analyst estimates of $84.56 million. As a group, analysts anticipate that CareDx, Inc will post -0.9 earnings per share for the current year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.